Trials / Completed
CompletedNCT05757531
A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male Participants
Disposition of [14C]-LY3437943 Following Subcutaneous Administration in Healthy Male Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to is to look at how much LY3437943 gets into the bloodstream and how long the body takes to get rid of it in healthy male participants. This study will involve a single dose of 14C radiolabeled LY3437943. his means that a radioactive tracer substance, C14, will be incorporated into the study drug to investigate the study drug and its breakdown products and to find out how much of these pass from blood into urine, feces and expired air. The study will last up to approximately 15 weeks including the screening period of 28 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [¹⁴C]-LY3437943 | Administered SC. |
Timeline
- Start date
- 2023-03-17
- Primary completion
- 2023-06-23
- Completion
- 2023-06-23
- First posted
- 2023-03-07
- Last updated
- 2023-07-05
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05757531. Inclusion in this directory is not an endorsement.